Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.
This video supports improved clinical awareness and encourages comprehensive care strategies for patients living with both CRSwNP and asthma.
Explore the role of type 2 inflammation in the production of mucus plugs in asthma and the effects these plugs can have on patients.
Join leading pulmonologists Drs. Njira Lugogo, Simon Couillard, and Mario Castro, as they explore the role of type 2 inflammation in the pathogenesis of mucus plugging in the airways, the burden of excess mucus in patients with moderate-to-severe asthma, and how reducing airway mucus may lead to improved long-term patient outcomes.

In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.
Join Drs. Njira Lugogo, Simon Couillard, and Mario Castro for a session exploring the link between pathogenic mucus and impaired lung function in patients with moderate-to-severe asthma and the potential for disease modification with targeted therapy.
Explore how type 2 inflammation drives the production of eosinophils in severe asthma.
At ATS 2026, the Sanofi & Regeneron ADVENT Booth #1301 brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.

Learn how FeNO, a noninvasive biomarker for type 2 inflammation, can be used to optimize care for asthma patients.
Join experts Frederik Trinkmann, Monica Kraft, and Arnaud Bourdin on an ADVENT educational symposium, “Distal Airways, Central Role? Clinical Insights Into Type 2 Severe Asthma."
Learn about the multifaceted burden of uncontrolled pediatric asthma on patients and their caregivers.
At ATS 2026, the Sanofi & Regeneron ADVENT Booth brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.